Clinical trials: Metastatic Breast Cancer, Colon Cancer
Breast Cancer, Colorectal Cancer
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00898781
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Breast Cancer, Colorectal Cancer
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to the cancer cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00128622
- Testing
- denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Kim Lyerly
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Pancreatic Cancer
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic…
- Conditions
- Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02210364
- Testing
- lurbinectedin (PM01183), capecitabine
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 81 people
- Sponsor
- PharmaMar
Neoplasm Metastasis, Colorectal Neoplasms
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer…
- Conditions
- Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
- Trial name
- NCT02124148
- Testing
- Prexasertib, Cisplatin, Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
- Trial name
- NCT03256344
- Testing
- Talimogene Laherparepvec, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Breast Cancer, Colorectal Cancer
Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer
RATIONALE: Collecting information over time about patients' and health care providers' understanding of pain and fatigue and providing education about pain and fatigue management may improve quality of life.
- Conditions
- Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer
- Trial name
- NCT00900835
- Testing
- educational intervention, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer Metastatic, Breast Cancer Female
Evolution of the Physical Condition in Treated Cancer Patients
Adaptated Physical Activity (APA) during treatment of cancer is one of the actual global health recommendation because of the benefits observed in several parameters evaluated in many clinical studies.
- Conditions
- Non-small Cell Lung Cancer Metastatic, Breast Cancer Female, Colon Cancer
- Trial name
- PROTECT-01 (NCT03956641)
- Testing
- Adaptated Physical Activity
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Paul Strauss
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Colorectal Cancer
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Trial name
- NCT00305643
- Testing
- Capecitabine, Celecoxib, Radiation Therapy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Colorectal Cancer
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
The purpose of this study is to evaluate the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib.
- Trial name
- ProMETheX (NCT01847599)
- Testing
- Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Jean Perrin
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Metastatic Colorectal Cancers, Metastatic Gastric Cancers
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable…
- Conditions
- Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers
- Trial name
- MOMENTUM1 (NCT01843725)
- Testing
- capecitabine, aflibercept
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Colorectal Cancer
Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00049608
- Testing
- mistletoe extract, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT01174121
- Testing
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)